Please ensure Javascript is enabled for purposes of website accessibility

Seattle Genetics (SGEN) Q4 2020 Earnings Call Transcript

By Motley Fool Transcribing - Feb 12, 2021 at 5:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

SGEN earnings call for the period ending December 31, 2020.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Seattle Genetics (SGEN 2.12%)
Q4 2020 Earnings Call
Feb 11, 2021, 4:30 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Operator

Good day, and welcome to the Seagen fourth-quarter and full-year 2020 financial results conference call. [Operator instructions] Please note that this event is being recorded. I would now like to turn the conference over to Ms. Peggy Pinkston, vice president of investor relations.

Please go ahead.

Peggy Pinkston -- Vice President of Investor Relations

Thank you, operator, and good afternoon, everyone. I'd like to welcome all of you to Seagen's fourth-quarter and full-year 2020 financial results conference call. This afternoon, we issued a press release with our results and that press release and supporting slides are available on our website in the investors section, events and presentations page. Speakers on our call today will be Clay Siegall, president and chief executive officer; Chip Romp, executive vice president, commercial U.S.; Todd Simpson, chief financial officer; and Roger Dansey, chief medical officer.

Following our prepared remarks, we'll open the line for questions. We aim to keep this call to one hour and to ask that you limit yourself to one question to give everyone an opportunity to participate in Q&A during our call today. Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2021 financial outlook, anticipated product sales, revenues, costs and expenses, and potential clinical and regulatory milestones, including data readouts, regulatory submissions, and approvals. Actual results or developments may differ materially from those projected or implied in these forward-looking statements.

Factors that may cause such a difference include the difficulty in forecasting sales, revenues and expenses, impacts related to the COVID-19 pandemic, and the uncertainty associated with the pharmaceutical development and regulatory approval process. More information about the risks and uncertainties faced by Seagen is contained under the caption risk factors included in the company's current report on Form 8-K filed with the Securities and Exchange Commission on December 29th, 2020 and the company's subsequent reports filed with the SEC. And now I'll turn the call over to Clay.

Clay Siegall -- President and Chief Executive Officer

Thank you, Peg, and good afternoon, everyone. The past year was pivotal in the evolution of our business. We expanded our geographic footprint and operations beyond the United States and Canada with presence across greater Europe as we prepare for additional launches of TUKYSA. We are now a multiproduct global oncology company with substantial financial strength to fuel ongoing company investments.

We have laid a strong foundation for continued growth and the ability to bring important medicines to cancer patients in need. I'll start with a summary of our recent financial performance. We reported record 2020 product sales in our territories of just over $1 billion, reflecting a 59% annual increase. These results were driven by successful PADCEV and TUKYSA launches, as well as, continued strong ADCETRIS sales.

Total revenues were $2.2 billion in 2020 which included royalties and collaborations, notably our new strategic partnership with Merck. We ended 2020 with $2.7 billion in cash and investments which strongly positions us to continue advancing our programs. In 2021, we expect to see continued growth of PADCEV and TUKYSA and maintain market share for ADCETRIS with anticipated product sales in our territories of approximately $1.3 billion. Todd will walk us through our 2021 guidance and Chip will discuss the commercial dynamics but first, I'd like to reflect upon the past year.

During 2020, we delivered multiple important business, regulatory, and development milestones. I'd like to provide you with a few highlights, beginning with ADCETRIS. Our partner, Takeda, gained more ex U.S. approvals, including in China.

Additionally, in December, we presented data from the ECHELON-1 and ECHELON-2 Phase 3 trials at ASH, demonstrating robust and durable remissions at five years. This is a clinically meaningful and important milestone in a cancer patient's journey. We are committed to maximizing ADCETRIS patient reach through our clinical development program in Hodgkin lymphoma and other CD30 expressing malignancies. Next, I'll turn to PADCEV, a first-in-class ADC that we're developing and commercializing in collaboration with Astellas.

PADCEV has shown rapid adoption since its FDA accelerated approval for metastatic urothelial cancer just over a year ago. In 2020, we announced positive top-line results from two PADCEV studies. This included strong data from our single-arm Phase 2 trial insists ineligible metastatic urothelial cancer patients previously treated with an immune checkpoint inhibitor. We expect to submit these data to FDA in a supplemental BLA within the next few weeks.

Last year, we also reported top-line results from a randomized Phase 3 trial in patients with previously treated metastatic urothelial cancer. Results demonstrated that PADCEV significantly improved overall survival and progression-free survival versus standard of care chemotherapy. These data will also be submitted to FDA resulting in two concurrent supplemental BLAs in the next few weeks. In addition, global submissions for these trials are planned to support marketing applications in the EU and Japan later this quarter.

Also last year, we received breakthrough therapy designation for PADCEV in combination with KEYTRUDA in first-line metastatic urothelial cancer. We are currently enrolling two trials designed to support approval in first-line metastatic patients. One, to support accelerated approval in CIS-ineligible patients and the other to support global approval in patients regardless of platinum eligibility. Our goal is to redefine first treatment for metastatic urothelial cancer patients around the globe.

Finally, in 2020, we made significant headway in exploring earlier stages of bladder cancer. In collaboration with Astellas and Merck, PADCEV is being tested in two randomized Phase 3 trials in CIS ineligible and CIS eligible muscle-invasive bladder cancer patients. Now on to TUKYSA, a best-in-class HER2 TKI for HER2-positive metastatic breast cancer patients with and without brain metastasis. In 2020, TUKYSA was also approved in the United States, as well as, Australia, Canada, Singapore, and Switzerland under the FDA's project Orbis.

In December, we received a positive CHMP opinion recommending European Commission approval of TUKYSA in the EU and we are preparing for its potential launch further extending to TUKYSA's. Lastly, in order to accelerate the commercialization of TUKYSA in regions beyond the U.S., Canada, and Europe, we entered into a strategic collaboration with Merck in 2020. Our three currently approved products are important first-in-class or best-in-class medicines that have been embraced by oncologists. We are making substantial investments in their continued development which will provide growth catalysts in future years.

We believe that each of the brands have blockbuster potential. ADCETRIS, is a mainstay in the treatment of CD30 lymphomas and has achieved strong market penetration in its six indications. Global sales of ADCETRIS in 2020 were approximately $1.2 billion and nearly 83,000 patients around the world have received ADCETRIS therapy. We expect that the impact of COVID-19 which is leading to fewer frontline Hodgkin lymphoma diagnosis will resolve in time, but this is hard to predict.

We believe that future growth of ADCETRIS will be primarily based on label expansion supported by our multiple ongoing trials that we expect to read out in the next few years. PADCEV has become the standard of care in its current labeled indication. We expect that both supplemental BLA submissions, if approved, will further strengthen PADCEV's role in the treatment of patients with advanced metastatic urothelial cancer. Looking toward first-line metastatic bladder cancer, we expect to complete enrollment in the Cohort K accelerated approval trial by the end of this year.

Factoring in a follow-up period to observe duration of response data from this cohort could support a supplemental BLA in 2022. In addition, three large Phase 3 trials are currently enrolling in first-line metastatic urothelial cancer and muscle-invasive bladder cancer. These trials are intended to serve as the basis for multiple global submissions in the future. TUKYSA is an important medicine that has been rapidly adopted by oncologists.

We're planning launches in Europe during 2021, as well as, seeking reimbursement approvals on a country-by-country basis. Additionally, we're conducting several large potentially pivotal trials in breast, gastric, and colorectal cancers. We expect to complete enrollment in the mountaineer trial in colorectal cancer patients by the end of 2021 while our other studies will continue to enroll. Building on the success of ADCETRIS with our six labeled indications, we expect PADCEV and TUKYSA to reach even more patients in the future.

This is based on our ongoing extensive clinical development programs that Roger will describe in detail. I'll now turn to our late-stage clinical development programs, tisotumab vedotin, also known as TV and ladiratuzumab vedotin, known as LV. Yesterday, we and Genmab announced the submission of a BLA for TV in patients with recurrent or metastatic cervical cancer, positioning it to be our fourth commercial product. This is a significant milestone for Seagen and would further expand our commercial portfolio.

We also recently initiated the Innovative 301 Phase 3 study in metastatic cervical cancer which is intended to support global regulatory applications and serve as the confirmatory trial. Aligned with our goal of addressing the high unmet need for patients with hormone receptor positive and triple-negative breast cancer, last year, we announced a global collaboration with Merck to co-develop and co-commercialize LV. The collaboration is intended to accelerate the development of LV and focuses on evaluating this highly active ADC as monotherapy, and in combination with KEYTRUDA in LIV-1 expressing solid tumors. As we look ahead to 2021 and beyond, we are focused on three strategic priorities to drive continued innovation growth.

The first is to maximize the global potential of our three approved medicines through robust clinical development programs and exceptional commercial execution. The second priority is to advance late-stage programs toward securing approvals for products, including TV and LV. And the third is to expand our already strong and innovative early stage pipeline through continued leadership and innovation in the ADC space, internal R&D investments and corporate development opportunities. Focusing on these strategic pillars will ensure our organization is aligned to deliver substantial value to our key stakeholders, notably stockholders, our employees, and especially answer patients.

Next, I'll turn the call over to Chip to discuss our commercial activities. Then Todd will comment on our financial results and 2021 guidance. After that, Roger will discuss our clinical development activities and key milestones for the year ahead. Chip?

Chip Romp -- Executive Vice President, Commercial U.S.

Thank you, Clay. The commercial team closed out a very successful year with a solid fourth quarter. Launching two drugs in these unprecedented times was a difficult task. Through strong digital marketing strategies, creativity, and outstanding customer relationships our team delivered.

Successful launches of PADCEV and TUKYSA drove 59% total net product sales growth in 2020 over 2019. I would like to thank all my commercial colleagues for their dedication and efforts in 2020 to ensure appropriate patients received our products. Starting with ADCETRIS, we reported fourth-quarter sales of $164 million and $659 million for the year, a 5% increase over the full year in 2019. We continue to see an impact on ADCETRIS sales due to the pandemic.

Based on claims and electronic medical records data, new Hodgkin lymphoma diagnosis trends continue to be approximately 15% lower than historic levels. We are now promoting the five-year follow-up data from the ECHELON-1 trial in frontline HL and early reactions to these important data have been favorable. Five-year outcomes are an established standard and we expect that the durable advantage of ADCETRIS will drive incremental share. Moving on to PADCEV, fourth-quarter sales were $69 million, an increase of 11% over the third quarter of 2020.

Full-year PADCEV sales were $222 million. We received rapid adoption in our labeled indication and look forward to promoting upon approval, the overall survival data observed in the EV-301 trial and the strong cohort two data in metastatic urothelial cancer. Both indications would meet a significant unmet need for patients who have received a prior PD-1 or PD-L1 inhibitor. Our guidance takes into consideration our high market share in our current labeled indication and evolving market dynamics, such as increasing use of PD-1 or PD-L1 inhibitors in the frontline.

We are confident that PADCEV is well-positioned this year for continued growth. Transitioning to TUKYSA, fourth-quarter sales were $61 million, a 45% increase over the third quarter. Full-year sales of TUKYSA were $120 million. We continue to see adoption of TUKYSA across its strong label and payer coverage continues to be solid.

We are pleased with the growth we are seeing in both the community and academic settings. I will now turn the call over to Todd.

Todd Simpson -- Chief Financial Officer

Great. Thanks, Chip, and thanks to everyone for joining us on the call this afternoon. Today, I'll summarize our financial results for the fourth-quarter and full-year in 2020. I'll then provide our financial outlook for 2021.

Total revenues were $601 million in the fourth quarter and $2 billion for the full year in 2020. This included net product sales up $294 million for the fourth quarter and $1 billion for the full year. This is the first time we have recorded net product sales of $1 billion and this reflects the substantial growth in now a diverse commercial portfolio which includes three important drugs. Royalty revenues were $39 million in the fourth quarter and $127 million for the full year in 2020.

Royalty revenues are primarily driven by increasing sales of ADCETRIS by Takeda, and to a lesser extent, sales of Polivy by Roche and BLENREP by GSK, both of which are ADCs that utilize Seagen technology. Collaboration and license agreement revenues were $268 million for the fourth quarter and $1 billion for the full year in 2020. Notably, the full year of 2020 included $975 million related to the LV and TUKYSA deals with Merck, of which, $250 million was recorded in the fourth quarter. These collaborations are significant for the company, both financially and strategically and will accelerate the development of LV.

Cost of sales in the fourth quarter of 2020 was $62 million and $218 million for the full year. This included product cost of sales and royalties for each of our three brands and the PADCEV profit share to Astellas which was $32 million in the fourth quarter and $105 million for the full year in 2020. In addition, cost of sales included two TUKYSA related items, noncash amortization of acquired technology costs of approximately $6 million per quarter that began in the second quarter of 2020 and a sublicense fee that was paid related to the TUKYSA license agreement with Merck. R&D expenses were $216 million in the fourth quarter and $827 million for the full year in 2020.

Growth over 2019 primarily reflected increased investment across our pipeline aimed at extending the use of our commercial products through expanded labels, as well as, investment in the development of our earlier stage programs. SG&A expenses were $158 million in the fourth quarter and $534 million for the full year in 2020. These are planned increases over 2019 and reflect U.S. commercialization of PADCEV and TUKYSA, and our European expansion as we prepare for the TUKYSA launches later this year.

Regarding the profit recorded for the fourth quarter and for the full year in 2020. This is the result of revenue recognized under our two new collaborations with Merck. Our long-term growth strategy continues to remain on investment to maximize the potential of our approved products and in advancing our pipeline. We ended the year with $2.7 billion in cash and investments which includes proceeds from the $1 billion equity investment from Merck in the fourth quarter.

This positions us strongly to advance our plans in 2021 and beyond. Now regarding our 2021 financial outlook, I'll begin with revenue guidance. First, we expect total revenues to be in the range of approximately $1.4 billion to $1.5 billion. This breaks down as follows: We expect total product sales to be approximately $1.28 billion to $1.34 billion which includes ADCETRIS sales in the range of $675 million to $700 million, PADCEV sales in the range of $310 million to $325 million and TUKYSA sales in the range of $300 million to $315 million.

Clay and Chip provided some context around what we envisioned to be the growth drivers for each of the brands in the near and longer-term. Next, with respect to royalty revenues, we expect them to be in the range of $125 million to $135 million, primarily reflecting sales of ADCETRIS by in its territory and to a lesser degree, contributions from POLIVY and BLENREP. Finally, collaboration revenues are now primarily event-driven and dependent upon progress by our ADC collaborators. We expect these revenues to be less than $20 million in 2021.

Beginning next year, we expect collaboration revenues will reflect contributions from PADCEV sales by Astellas in its territories. I'll now turn to expenses. Cost of sales is expected to be in a range of $270 million to $300 million. This will be driven by increased product sales across all brands and a higher profit share payment to Astellas as a result of higher expected PADCEV sales.

Cost of sales will also reflect third-party royalties owed, as well as, noncash amortization. R&D expenses are expected to be in the range of $900 million to $1 billion, primarily related to two items. First, investment in clinical trials to expand ADCETRIS, PADCEV, and TUKYSA into additional indications; and second, increased investment to advance our earlier-stage pipeline that includes nine other programs in clinical development. We believe that these investments are important to our long-term growth.

SG&A expenses are expected to be in a range of $650 million to $725 million as we continue to focus on commercial execution to drive growth of our three approved products. This guidance also includes the global infrastructure to support the launch of TUKYSA in Europe. Taken together, our 2021 guidance reflects both that we continue to see significant opportunity for our approved medicines and that we will continue efforts to develop new medicines for unmet medical needs. And with that, I'll turn the call over to Roger.

Roger Dansey -- Chief Medical Officer

Thank you, Todd, and good afternoon, everyone. Today, I will provide an update on recent progress for our approved medicines and pipeline programs and will outline key milestones anticipated in the year ahead. Beginning with ADCETRIS, we presented the important five-year follow-up data at ASH for the Phase 3 ECHELON-1 trial. ADCETRIS in combination with AVD, resulted in superior long-term outcomes when compared to ABVD and in frontline advanced Hodgkin lymphoma.

The clinically meaningful improvement in PFS has continued since the primary analysis, reflecting the durable benefits seen with the ADCETRIS regimen. Notably, we also saw fewer second malignancies and more pregnancies in those who received ADCETRIS plus AVD versus those who are treated with ABVD. We are pleased with these aspects of the data in a population of generally young patients with families. Going forward, we continue to see multiple opportunities for ADCETRIS and are advancing trials in Hodgkin lymphoma, PTCL, and DLBCL.

Most recently, we have begun enrolling a trial evaluating ADCETRIS as an immunomodulatory agent in combination with KEYTRUDA in solid tumors. Turning now to PADCEV. Full results from the EV-301 trial and Cohort 2 of the EV-201 trial, both conducted in patients with previously treated metastatic urothelial cancer will be presented tomorrow in oral presentations at ASCO-GU. The Phase 3 EV-301 data demonstrated a clinically meaningful and statistically significant 30%, reduction in the risk of death among patients who received PADCEV compared to those who received chemotherapy.

In this new era of frequent checkpoint inhibitor use for metastatic urothelial cancer, PADCEV is the first drug shown to reduce the risk of death after patients who received a platinum chemotherapy and a checkpoint inhibitor. PADCEV has also shown a clinically meaningful response rate in patients who were ineligible for cisplatin in the metastatic setting and were treated with a checkpoint inhibitor. EV-301 and EV-201 data will be submitted to regulatory authorities this quarter to support U.S. and global approvals.

Another key component of our PADCEV development program is our two-pronged approach to support approval in the first-line metastatic urothelial cancer setting. We plan to complete enrollment of cisplatin ineligible patients receiving PADCEV plus KEYTRUDA in Cohort K of the EV-103 trial by the end of this year. And if the data are supportive, a supplemental BLA could occur in 2022 after appropriate follow-up for duration of response. We continue to enroll patients into the Phase 3 EV-302 global trial which includes cisplatin eligible patients, evaluating PADCEV plus KEYTRUDA compared to a platinum-containing chemotherapy regimen.

As we move passive into earlier stages of bladder cancer, we and our partner, Astellas, together with Merck, recently initiated the KEYNOTE-B15 or EV-304 trial to evaluate PADCEV in combination with KEYTRUDA, and in cisplatin eligible muscle-invasive bladder cancer. This trial is in addition to the ongoing trial in cisplatin ineligible muscle-invasive bladder cancer patients, known as KEYNOTE-905 or EV-303. Additionally, we are also in advanced planning for a trial to examine PADCEV administered directly into the bladder in non-muscle invasive bladder cancer patients. Lastly, since the launch of PADCEV, we have continued to monitor the safety of our products in clinical trials and in the post-marketing setting.

As a reminder, Nectin-4 is expressed in the skin and rashes common, but is generally mild and reversible. Severe rashes, however, do occur and are described in the current U.S. prescribing information. Severe cutaneous adverse reactions, including fatal cases of Stevens Johnson syndrome and toxic epidermal necrolysis have occurred in patients treated with PADCEV in the post-marketing setting and during clinical trials.

With patient safety being our highest priority, we are communicating the accounts of these rare events by a litter, together with updated recommendations to healthcare providers who may treat patients with urothelial cancer. We are also working with the FDA regarding updates to the U.S. prescribing information to reflect these events. The overall benefit risk balance remains favorable for the use of PADCEV in approved indications.

PADCEV provides significant benefit to fight and met need population with metastatic urothelial cancer which is further supported by our most recent data showing improvement in overall survival in the indicated population. Moving on, at the San Antonio Breast Cancer Symposium in December, TUKYSA was featured in several abstracts. A key presentation provided new analyses from the pivotal HER2CLIMB trial, demonstrating consistent improvements in progression-free survival, overall survival, and objective response rate regardless of whether patients were hormone receptor positive or hormone receptor negative. With regard to our clinical development program, we are excited to be expanding our evaluation TUKYSA into earlier lines of breast cancer treatment and into GI cancers.

To this end, we are currently advancing eight TUKYSA clinical trials, of which five have registrational intent. Now I would like to turn to one of our late-stage programs, tisotumab vedotin. For women with metastatic cervical cancer, who progress on first-line treatment, standard therapies typically have low objective response rates of less than 15%, and median overall survival ranging from six to nine months. The Innovative 204 trial demonstrated clinically meaningful durable responses with an ORR of 24% and median duration of response of 8.3 months and are the pivotal data included in the recently announced BLA submission.

We are motivated at the prospect of a fourth approved medicine that could make a meaningful difference to metastatic cervical cancer patients with such a high unmet need. Moving on to ladiratuzumab vedotin, we are working with Merck to accelerate the development of LV, both as a monotherapy and in combination with KEYTRUDA, our development program includes trials in triple-negative and hormone receptor positive breast cancer, as well as, a basket trial in eight other liver and expressing solid tumors. We are making progress on optimizing the dose and schedule of LV and have extended the weekly schedule evaluation to the combination of LV with KEYTRUDA. Turning now to our earlier stage pipeline.

We have in the clinic three novel ADCs, two of which use our vedotin payload, and four effector function enhanced antibodies using our sea technology. Our most recent drug to enter Phase 1 is our novel ADC, SGN-STNV. This targets silo [Inaudible], a carbohydrate antigen which is highly expressed across multiple solid tumors. I would now like to summarize some of the important upcoming milestones that we are looking forward to in 2021.

Beginning with regulatory, we have just submitted the TV BLA and look forward to working with the FDA on the application. Additionally, we look forward to hearing from regulatory authorities in Europe on our TUKYSA marketing authorization application. And PADCEV will be submitted to regulators in the U.S., Europe, and Japan, by the end of this quarter. Moving to clinical trial activities.

We expect to complete enrollment in the pivotal Cohort K of the PADCEV EV-103 trial and the pivotal TUKYSA near trial by the end of 2021. We have opened the innovative 301 global confirmatory trial and we have the potential to initiate several other pivotal trials across our pipeline in 2021. Finally, we plan to have multiple data readouts this year. This includes data from LV and multiple Phase 1 programs, such as SEA-CD40, as well as, data from TV in solid tumors other than cervical cancer.

We also plan to submit multiple INDs for novel product candidates during the course of the year. I look forward to sharing further details and developments as the year progresses. Now I'll turn the call back over to Clay.

Clay Siegall -- President and Chief Executive Officer

Thank you, Roger. I'm proud of the remarkable progress we have made as a company over the past year despite the challenges of COVID. We have set the stage for Seagen's next phase of innovation and execution, and the company has never been stronger and better positioned for growth. We have an expanding commercial portfolio, deep pipeline, broad geographic footprint, powerful partnerships, and a focused strategy.

This will, in turn, increase our ability to reach more cancer patients globally who need life-saving therapies. I would like to thank everyone listening to this call for your continued interest in Seagen and your ongoing support. Operator, please open the line for Q&A.

Questions & Answers:


Operator

[Operator instructions] And our first question today will come from Kennen MacKay with RBC Capital Markets. Please go ahead.

Kennen MacKay -- RBC Capital Markets -- Analyst

Hi, thanks for taking the question and congrats on the progress in 2020. What a year. Maybe just on the guidance for TUKYSA and for PADCEV. Just wondering if there's anything you can comment around what is baked into that in terms of indication expansion or geographic expansion or whether that's all upsiding that's just based on the current indication? Thank you.

Clay Siegall -- President and Chief Executive Officer

Sure. Ken, thanks for the question. Can you hear me, Ken?

Kennen MacKay -- RBC Capital Markets -- Analyst

Uh, yeah. Sure can.

Clay Siegall -- President and Chief Executive Officer

OK, good. Just want to make sure. You asked questions about TUKYSA and PADCEV. So, first of all, we're really excited that we have three approved drugs and our launch for both PADCEV and TUKYSA has been largely through -- either largely are all through COVID, so we've had to come up with a new way to launch drug.

We -- on PADCEV, we're now a standard of care for advanced urothelial cancer patients who received platinum and PD-1 and so we're in very good shape with that. We've had great progress. Chip, would you like to give a little bit of color on the guidance and what it really reflects?

Chip Romp -- Executive Vice President, Commercial U.S.

Sure, Clay. So we're monitoring ongoing changes in the marketplace. We're seeing a move of PD-1 and PD-L1 utilization into the frontline which is, in essence, an expanded PADCEV's treat location population. So that is a key driver for us in 2021.

With regard to TUKYSA, we continue to see increased utilization in both patients with brain metastases and patients without. So we're really focused for 2021 for promoting the full breadth of the label that we have.

Operator

And our next question will come from Geoff Meacham with Bank of America. Please go ahead.

Geoff Meacham -- Bank of America Merrill Lynch -- Analyst

Good afternoon, guys. Thanks for the question. I just had a couple of quick ones. Roger, when you look at the PADCEV and firts line opportunity from Cohort K, what's the normal duration of response from chemo that you'd expect? And are there ways to win, let's say, on an equivalent ORR, but perhaps better tolerability? And then for Todd or Chip, just also on guidance.

Just wanted to ask how much of a continued headwind from COVID is reflected? And is there a way to quantify it or at least tease out which products could be affected? Thank you.

Clay Siegall -- President and Chief Executive Officer

Jeff, thanks for both of the questions. Let's start with Roger talking a little bit about the frontline PADCEV story where we have actually two frontline trials, but I think Jeff is focused on Cohort K. Roger, you can discuss what you'd like to on that frontline trial basis.

Roger Dansey -- Chief Medical Officer

Sure. Yeah. Thanks, Clay and thanks for the question, Jeff. It's an interesting one.

So as you know, the data we've generated with PADCEV and Keytruda is remarkable. It is, of course, a single-arm trial. It's 45 subjects but we have a response rate that is substantially better than anything one could generate with standard of care. The information around -- so I think our expectation, our hope is that there will -- there won't be equivocation on the ORR.

Obviously, the data has to play out. With regard to durability, what's really important, as you know, is when you give a PD-1 inhibitor, it's one of the absolute hallmarks, the durability. So as high as the ORR is in the data generated to date, the long-term outcome, such as durability of response and progression-free survival, all are equally remarkable. With standard chemotherapy, PFS is measured in a sort of seven-month period.

I don't have a specific number for DOR for you because it's not often reported. But it's hard, again, if we can recapitulate even to a reasonable degree that better we've generated so far, I think we'll have a compelling story to tell.

Clay Siegall -- President and Chief Executive Officer

And then on the guidance front with -- you know, Jeff, you're asking a little bit about headwinds potentially with COVID. And certainly, we -- you know, every company would be remiss to say, everything is perfectly normal with COVID there. I mean there was a big article in FierceBiotech, I think, within the last two days about how oncology clinical trials are 60% down in enrollment. Ours are doing well.

We're not 60%, but I certainly understand the difficulties of running clinical trials during COVID. Also, we've guided patients just coming in to get therapy, whether it's first-line Hodgkin lymphoma or older patients coming in with, for example, bladder cancer. So there's certainly some headwinds, but we've done great, I think, really getting our exciting medicines out. You know, Chip, would you like to -- or I'll start with Chip and then, Todd, if you have something you'd like to add, it'd be great.

Chip, any thoughts on the guidance as per-COVID headwinds?

Chip Romp -- Executive Vice President, Commercial U.S.

Yeah. Well, so it's obviously difficult to predict what's going to take place with the pandemic. There's no doubt that it's been a headwind. But I would tell you, the teams have adapted well with regard to our promotional efforts.

We've altered a lot of the digital mix that we have from a marketing standpoint. We're putting an emphasis on that and so we're pleased with the results that we're seeing so far.

Todd Simpson -- Chief Financial Officer

Yeah and this is Todd. I'll maybe add a couple of thoughts. With respect to ADCETRIS, it's a little bit easier to correlate COVID effect with what's happening in the marketplace. Chip has previously talked about and we've talked about for a few calls now that we're seeing about a 15% reduction in the diagnosis rate of frontline Hodgkin lymphoma.

We can get to those data through review of things like electronic medical records. With drugs like TUKYSA and PADCEV, it's a little harder to pinpoint exact causality. But to Clay's point, I think, we're all experiencing a little bit of pain with COVID. Now with that in mind, I think we're all hopeful that we're just about to get behind this thing.

It's hard to speculate on when that might happen, but we're hopeful that as the pandemic resolves that things will come back to normal a little bit.

Geoff Meacham -- Bank of America Merrill Lynch -- Analyst

Thanks, guys. Thanks, Clay. Congrats on all the progress.

Clay Siegall -- President and Chief Executive Officer

Thanks, Geoff.

Operator

Your next question will come from Cory Kasimov with J.P. Morgan. Please go ahead.

Cory Kasimov -- J.P. Morgan -- Analyst

Hey, good afternoon, guys. Thanks for taking my questions. I have one on PADCEV. With product on the market for a little over a year now, curious if you can tell us more in the average number of cycles you're seeing per patient in the real world, kind of how that's evolving, as well as, sort of the latest in terms of an annualized cost of treatment per patient? And Roger, you mentioned the rash that you've seen and you've alerted doctors, too.

Is that impacting things in any material way on the commercial front? Thank you.

Clay Siegall -- President and Chief Executive Officer

Cory, thanks for the question. You know, as far as the average cycles that we were out there, we aren't -- I don't think we've really discussed that. We discussed like how long in general we treat people, but it's really different for a lot of patients and the annualized cost. So have we given some information on that.

Chip, would you like to talk a little bit about roughly the cost per patient with PADCEV? And clearly, this is not in the frontline, this is in the relapse setting which is our current label. So Chip, do you have any comments on that?

Chip Romp -- Executive Vice President, Commercial U.S.

Yeah, I do, Clay. So if I were to -- just to kind of ballpark the net price associated with this, reflecting gross-to-net and discounts that are given associated with PADCEV would be about 90K, $90,000 per patient.

Clay Siegall -- President and Chief Executive Officer

Yeah. So thank you. So that's about right and so when people ask me, I usually somewhere in that $90,000 to $95,000. So it's about really where we are, depends on the patient and their size, etc.

On the question you have on the rash, we -- in our initial USPI we described skin reactions, including some that are severe. And Nectin-4 is a great target. Nectin-4 binds to tumors like crazy, especially urothelial tumors and some other ones that we're screening, and you'll hear more about that about our basket study, but it also buys like almost every antibody. It has some normal tissue cross reactivity and so we've known about the skin and there are some patients that get rash.

And we have a section in there with warnings and precautions, so that doctors are well aware of what this is and so we call it out. And most of the time, it's nothing to write home too much about it. Sometimes it gets more severe. We think that PADCEV has a very favorable risk benefit and we've shown that through overall survival in the 301 study which we'll be presenting the data tomorrow.

So that's something really to look forward to. When you see an OS benefit in rapid control of the disease, you have to weigh that against any of the side effects of any drug. And we think that doctors are well aware of this, are used to using this and having the side effects that almost every cancer drug has is, the goal is really to make sure that doctors are aware. They try to put it in the best light so that they can watch it and if there's anything happening with a patient, they could they could manage it correctly or hold drug or do whatever they need to.

And that's the case for all of our drugs because looking at patient safety is No. 1 issue. I don't know if that answered your question? Roger, do you want to put in any thought on this about --

Roger Dansey -- Chief Medical Officer

No, sure. And I think Cory's question around, does this actually impact duration of therapy? I think Clay has made the right points which is rash does occur, it's generally mild and transient, and does not meaningfully interfere with therapy. For these very rare events, obviously, the drug needs to be discontinued. So any bad reaction would require discontinuation, but the frequency of those events is low.

So I don't think we believe that this changes in any way the way PADCEV is being used or the length of therapy that it's currently used at.

Cory Kasimov -- J.P. Morgan -- Analyst

OK. Thank you. I appreciate it.

Operator

And our next question will come from Salveen Richter with Goldman Sachs. Please go ahead.

Salveen Richter -- Goldman Sachs -- Analyst

Good afternoon. Thanks for taking my questions. Given the guidance for PADCEV only includes on label use, could you help us understand what the incremental market share will be when the additional indication comes on board or indications come on board this year?

Clay Siegall -- President and Chief Executive Officer

Salveen, thank you for the question and we have two submissions. The first one is what we call Cohort 2 which is the more frail and weak patients, these were the cis-ineligible patients. And then the second cohort of patients were -- or the second study that we reported is called our 301 study which is our global study. Roger can talk about both of those trials and maybe what they mean.

We put out the top-line data. Tomorrow we'll be at ASCO-GU. It just so happens it's tomorrow. We wish we could tell you more today, but we need to save it for the presentation at the conference by the investigators.

They deserve the right to prevent this. So we're sorry it ends up to be tomorrow, but we'll announce the full data of tomorrow and all that. So look for that and we'll present this. So maybe Roger could give you just a little color about these two trials.

And then Chip, you can maybe talk a little bit about what you think would add to market here and manage balancing what docs will be using off-label for what any new label could be doing. So Roger, do you want to start and kind of outline this?

Roger Dansey -- Chief Medical Officer

Sure. Sure. So Salveen, the randomized trial, EV-301 is essentially a recapitulation of Cohort 1. So it's the same population patients who've seen a platinum therapy followed by a PD-1 or PD-1 inhibitor and the important outcome is that overall survival is improved against standard chemotherapy.

And that standard chemotherapy is obviously suboptimal in terms of outcomes. I think we're really excited by that data. It is a complete affirmation of the value that PADCEV can bring to this population. And obviously, physicians will react differently in terms of level of evidence.

Those who believe that an overall survival signal is required before using a drug may be compelled by this, although we think we already have more than enough efficacy data to support PADCEV's use. With regard to Cohort 2, this is a -- it is a different population. It is an older population, a more frail population. There is a proportion of patients, obviously, who, at the time of their initial therapy for metastatic disease, are deemed cisplatin ineligible.

It's around about half the population are general cisplatin eligible. And then the decision is made to use a PD-1 or a PD-1 inhibitor rather than an alternative agent like carboplatin or some of the other chemotherapies. So there is a population that clearly gets treated like that. And effectively, that PD-1, PD-L1 is a first-line treatment.

And then the data that you'll see tomorrow and hopefully or find compelling, does demonstrate that PADCEV in that situation produces excellent response rates and very durable outcomes, including overall response -- I mean duration of response outcomes. So the exact size of that population, I think, may be quite difficult to define and Chip may comment on that. Suffice to say, that checkpoint inhibitors are used widely in cancer for good reason because they make a difference. But we think that we add meaningfully to the sort of armamenterium for physicians as they manage metastatic urothelial cancer.

Do you have any comments?

Chip Romp -- Executive Vice President, Commercial U.S.

Yeah. What I would add to that, Roger, thanks. I would characterize this as a smaller segment of the population, but nevertheless, a meaningful number of patients. I think it's an important unmet need.

PADCEV could offer, once approved, an important option for these patients and I think that's what we're looking forward to.

Salveen Richter -- Goldman Sachs -- Analyst

great. Thank you.

Operator

And our next question will come from Matthew Harrison with Morgan Stanley. Please go ahead.

Matthew Harrison -- Morgan Stanley -- Analyst

Great. Good afternoon. Thanks for taking my questions. Chip, I was wondering if you could just comment at all on what we may expect to see this year from, either the arbitration or the ongoing patent [Inaudible] that you have, just in terms of whether you would expect us to hear any resolution of that this year potentially? Thanks.

Clay Siegall -- President and Chief Executive Officer

So thanks for the question. So there's a lot of work ongoing with our legal dispute with the DS. I will tell you that -- and I will remind you that's a better way to say it, that we are not a litigious company. You know, more -- almost two and a half decades, and this is the first time we've had something like this.

So -- and you know, and so this is not our goal and also it'll make a difference in the life of cancer patients, but we're compelled to defend our IP and our contracts. And so there are two things going on, one is an arbitration about a contract and one is a patent infringement suit. So both of those are in play, both of them are very active and we -- there's just a lot of legal activity on it. I'm not an attorney, so I can't describe it all to you, but -- and it's confidential.

But it's not sitting still by any stretch and so things are moving along well on that. It is -- I would -- I really hope that there is some resolution on this year, but I can't promise you that. I'm not -- I really don't know how fast arbitrators work and courts work. But I -- we certainly would love to see this effort be completed at some point.

We feel we have a fantastic case. I mean, to us, it's a straightforward case and it's something that we think that we deserve value and so we'll see what happens. But thank you for the question. So -- and please stay tuned.

As soon as we have something to say, you bet, we will be announcing it.

Operator

And our next question will come from Michael Schmidt with Guggenheim. Please go ahead.

Michael Schmidt -- Guggenheim Securities -- Analyst

Hey, guys. Thanks for taking my questions. I think I heard you mention SEA CD40, one of your earlier-stage programs with updates here. And I think we've already seen some interesting early data at your R&D data but just curious if you could help us with expectations in terms of the data disclosures this year and how that might perform?

Clay Siegall -- President and Chief Executive Officer

Sure. It was hard to hear you, so I'll repeat the question for anyone who didn't hear. He asked about what we call SEA CD40 which is a drug that sometimes I just call S40, but it is a -- it's not an antibody drug conjugate. It is a effector function enhanced antibody through our SEA technology which basically through manufacturing very elegantly and simply, it competitively inhibits the terminal fucose from being added to an antibody, and it makes the antibody have some extraordinary properties which can be really helpful if you're looking at depleting tumor populations.

And so it's not an ADC but it's an empowered antibody by any other way of looking at it. And I've talked about it to say that I have interest in this and so usually, I don't -- you know me for a long time. I usually don't bring up drugs that I don't really have interest in. And certainly, we've developed a number of drugs that haven't made it past early trials and I think S40 is a very interesting drug.

We have committed to presenting data on that this year. So that's where we are on it. I really -- the data will be in pancreatic cancer where we've been focused on. I am excited to complete the work.

One of the things with pancreatic cancer and if you look historically at panc -- it's been a hard disease to treat. A lot of patients don't know they have the disease until they're pretty far along. It's different than some of the diseases which have obvious symptoms that you could see until it's too late. So unfortunately, pancreatic cancer is a poorly treated disease that really needs new medicines.

And so that's one of the exciting things I have because we have such a big interest in making a difference in patients' lives and have had for a couple of decades now. That pancreatic cancer has always been a top disease to treat, so we're excited to see if we can make a difference in these patients' lives and you know, the early data is very interesting and we -- I mentioned it at one or two calls that I was interested in. But if you look historically, there's a lot of times in pancreatic cancer, where you see some early data and hence -- and then folks do larger studies and it doesn't pan out. And so that's something that, you know, if you don't learn the lessons of history, you're doomed to repeat them again.

So we certainly have learned that, we've watched it, and so we took some very exciting -- interesting, exciting, early data, and we've expanded it pretty dramatically to try to get a really good handle on what responses are, what's the duration, maybe even an early way of looking at does this impact survival? So to see as best as we can, what the data means and then when we report the data, we also are -- as we look at the data and report the data, the question really is, what happens next? And I'm hopeful that when the data come out, the data is robust and it's exciting, and we decide to go into a pivotal trial and I don't know yet. We're not announcing that. We're not guiding. But your question was, what should we look for? Roger, do you have any other thing you want to mention about what they should look for?

Roger Dansey -- Chief Medical Officer

I think that just to sort of repeat, the scientific hypothesis we're testing is a strong one. There's good preclinical data, the combination of a CD40 agonist which we have had in the clinic, we already have evidence of single-agent activity in some other diseases. But in this construct, we are combining it together with the frontline chemotherapy which is Abraxane sort of gemcitabine-based chemotherapy together with a PD-1 inhibitor. And those three interventions, those are all sort of a [Inaudible] you know, the kill the cancer cell with the chemotherapy, stimulate antigen presentation with the CD40 and other things, by the way, from a mechanistic perspective and then make sure that the breaks are taken off any of the T cells.

So it's a very strong scientific hypothesis. As Clay said, we've enrolled a good number of patients, we will wait for the data to read out, and we'll make our determination, at that point as to what our next steps could be.

Michael Schmidt -- Guggenheim Securities -- Analyst

Great. Thank you.

Operator

And our next question will come from Gena Wang with Barclays. Please go ahead.

Sheldon Chuan -- Barclays -- Analyst

Hi, this is Sheldon Chuan on Gena -- on behalf of Gena. Thanks for taking our questions. Just two very quick one on the guidance, one is on PADCEV. In your prepared remarks, you mentioned that considering PADCEV current high -- their high market share, could you comment on what range of market share are we talking about, like 40% to 60% to 80% or higher? And another one is on the TUKYSA's guidance, what type of OUS revenue are you assuming in this guidance? Or are we talking about predominantly U.S.

sales for 2021? Thanks.

Clay Siegall -- President and Chief Executive Officer

Yeah. So thank you for the question. [Technical difficulty] On the specifics of market share percentage, that's not something we usually talk about because once you start going into percentage that every quarter, everyone's asking what's your percentage and all that and just -- it's kind of -- you know, we report our numbers and that's really what's important and so we feel it's standard of care. And Chip, if he wants to, can make a comment on the market share and what doctors think of this and with PADCEV.

On TUKYSA with the guidance, I think I'd like Todd to make a comment on -- you know, you asked a question about outside U.S. revenue and what's included in guidance. So why don't we start there with Todd. Todd, why don't you start on the guidance for TUKYSA.

Todd Simpson -- Chief Financial Officer

Sure, Gena. Thanks for the question. So the vast majority of our TUKYSA guidance is U.S. sales and we do have approvals in a few other countries under project Orbis.

And of course, we're looking forward to approvals broadly in Europe and starting to do that next year, but the vast majority of our guidance for TUKYSA is U.S.-based.

Clay Siegall -- President and Chief Executive Officer

OK. And then on -- going back to PADCEV on the market share and stuff like that. Chip, do you want to give a little color on that?

Chip Romp -- Executive Vice President, Commercial U.S.

Yeah. Thanks, Clay. So as a standard of care, I would say that we're well-positioned in 2021 to intersect at a very important point in these changing market dynamics. I think you're going to continue to see the PD-1 and PD-L1 utilization increase in frontline and I think that's going to put PADCEV in a favorable position.

Sheldon Chuan -- Barclays -- Analyst

Got it. Thanks so much.

Operator

And our next question will come from Andy Hsieh with William Blair. Please go ahead.

Andy Hsieh -- William Blair -- Analyst

OK, guys. Thanks for squeezing me in. Congratulations to everyone at Seagen for a banner year in 2000. So I had a question in kind of early stage bladder cancer for PADCEV.

It seems like you guys basically encroach and hold bladder cancer treatment paradigm everywhere overnight. So specifically in the non-muscle invasive bladder cancer, there's been some challenges associated with BCG supply. Just wondering for the intravesical use, are you looking at beyond BCG nonresponsive? Are you looking at patients who are not suitable for BCG as well, just to kind of broaden the opportunity be there?

Clay Siegall -- President and Chief Executive Officer

Yeah. Thank you for the question. We're really excited about PADCEV in all aspects of bladder cancer, like you say, whether it's metastatic, muscles invasive, where we have a lot going on, as Roger talked about. And our next area that we're going after is non-muscle invasive, but we've done a lot of work on there.

We haven't started the trials yet. We're well aware of the BCG challenges. Roger, do you want to give a little color on the intravascular use and what we're thinking?

Roger Dansey -- Chief Medical Officer

Yeah. So, Andy, it's a great question. Obviously, we're just beginning and we haven't disclosed any of the clinical trial plans, but we are -- you know, as we said in our prepared remarks, we are in advanced planning. We think the profile for PADCEV could be very favorable based on minimal systemic exposure and activity directly into the bladder.

The place to start, as you say, for all programs is in BCG nonresponsive, but if we find PADCEV is active in that population, we would obviously move or make plans to move into earlier lines of therapy. Again, it's a balance of how much benefit can we bring versus how much risk do we bring to bear on the circumstance and until we've generated the data we won't know. But I can tell you aspirationally, we would like to have PADCEV positioned if we can in non-muscle invasive bladder cancer, wherever it's appropriate to address the unmet need.

Andy Hsieh -- William Blair -- Analyst

OK. Thank you very much.

Operator

And our next question will come from Andrew Berens with SVBE or SVB Leerink. Please go ahead.

Andrew Berens -- SVB Leerink -- Analyst

Hi, thanks. I was wondering if there's a potential for increased rates or increased severity of skin rash when you give PADCEV with checkpoints versus PADCEV alone?

Clay Siegall -- President and Chief Executive Officer

Thank you very much for the question on that. You know, we're in trials now, as you know. Roger, can you comment as to -- we have some data that's actually been presented on this but we have ongoing trials. And so perhaps talking about anything we've seen in the on and the data that is -- that isn't going to be fair game.

Roger?

Roger Dansey -- Chief Medical Officer

Sure. So, Andy, and as you know, we believe -- we're confident in and we believe that the combination of PADCEV plus Keytruda has tremendous potential in bladder cancer, not just in metastatic, but in the muscle-invasive circumstance as well. And there is lots of scientific reasons to believe that a vedotin-based ADC may be particularly powerful when it's combined with the PD-1 inhibitor. From a safety perspective, obviously, all clinical trials that we run, we monitor safety carefully.

There are no changes to any of our plans with regards to what we are doing in our clinical trials. The data we presented to date which is around 45 subjects, where we did report overall skin rashes and [Inaudible] rashes and -- [Technical Difficulty]

Clay Siegall -- President and Chief Executive Officer

Roger, I just lost hearing you. Can you guys hear me?

Chip Romp -- Executive Vice President, Commercial U.S.

Yeah. I think it's really Roger.

Clay Siegall -- President and Chief Executive Officer

Yeah. OK. Well, we lost Roger. So, you know, Andy, are you still on?

Andrew Berens -- SVB Leerink -- Analyst

Yes. I'm still here. Yup.

Clay Siegall -- President and Chief Executive Officer

OK. Did you get enough of an answer from Roger?

Andrew Berens -- SVB Leerink -- Analyst

I think he was just about to talk about the data in the 45 patients, so -- he got cut off, unfortunately.

Clay Siegall -- President and Chief Executive Officer

Yeah. Yeah. So, Roger got cut off. You know, our data in the patients did not show anything that was -- that was obvious to us that there'd be a problem at all.

In fact, it shows the opposite. It showed that the patients did incredibly well on the two drugs together and we got breakthrough designation, and we're -- we've been enrolling a lot of patients in both the accelerated trial and the global trial. And so where we sit now, we're pretty darn excited on this and I don't know any reason that we would be inhibited from going forward, if that's what you're looking for.

Andrew Berens -- SVB Leerink -- Analyst

No, I was more interested in just if the rash is worse or more frequent and it could be more of a commercial issue?

Clay Siegall -- President and Chief Executive Officer

Yeah. We have not seen that.

Andrew Berens -- SVB Leerink -- Analyst

OK.

Clay Siegall -- President and Chief Executive Officer

In the trial that we presented on, we have not seen that.

Andrew Berens -- SVB Leerink -- Analyst

OK. Thanks. OK.

Clay Siegall -- President and Chief Executive Officer

We don't see any potential limitation in commercial with a combination at this point. Obviously, that's why you do big studies and you study these, so we'll have to see in the future. But for what we've seen to date, we see no issue with going forward commercial with that.

Andrew Berens -- SVB Leerink -- Analyst

Thank you.

Clay Siegall -- President and Chief Executive Officer

We've taken up PADCEV very well. I mean it's really -- I mean, it's really exciting to see a drug become standard of care in a metastatic setting pretty quickly.

Operator

And our next --

Peggy Pinkston -- Vice President of Investor Relations

Operator, we'll have time for one more question.

Operator

Absolutely and our question will come from Jay Olson with Oppenheimer. Please go ahead.

Jay Olson -- Oppenheimer & Co. Inc. -- Analyst

Oh, hey, congrats on all the progress and thank you for the update. I appreciate your three-pillared strategy and wanted to ask you about your plans to maximize the global potential of your portfolio which you've traditionally done through partnerships outside the U.S. And now since you're building a TUKYSA team in Europe, do you envision eventually building a global infrastructure and taking your early stage pipeline all the way from development through global registration and commercialization independently?

Clay Siegall -- President and Chief Executive Officer

So Jay, first of all, thank you for the question. Thank you for noticing that we have expanded on the back of TUKYSA -- on the back of TUKYSA to include greater Europe which is quite a lot of countries. So -- and our team there is just ready to go. We're really excited to start getting this out to patients in need and working with docs and all that.

So hopefully that soon, but as far as the future path there, what I would say is, it depends and I don't mean to be ignoring your question. It is not that easy for U.S. biotechs, or for that matter, U.S. pharma sometimes, to do a lot of work in, let's say, certain parts of Asia, especially the two biggest markets, Japan and China.

And so it is something that we're looking at closely as to what we would do with additional drugs and whether we would consider putting in Asia, for instance, at some of the big markets and so that's something we're talking about. I don't want to tell you, yes, we're going to do it or no. We do have great partners. We know all the best partners and distributors in different territories.

And whether we want a partnership or distribution is something you have to look at everywhere. But I'm really glad that we're going broader in a commercial way and I hope as part of our pillars that we continue to broaden out our global reach.

Jay Olson -- Oppenheimer & Co. Inc. -- Analyst

Great. That's super helpful. Thank you.

Operator

And this concludes the question-and-answer session. I'd like to turn the conference back over to management for any closing remarks.

Peggy Pinkston -- Vice President of Investor Relations

OK. Thank you, operator, and thanks, everybody, for joining us this afternoon. We look forward to staying in touch and I hope you have a good evening.

Operator

[Operator signoff]

Duration: 68 minutes

Call participants:

Peggy Pinkston -- Vice President of Investor Relations

Clay Siegall -- President and Chief Executive Officer

Chip Romp -- Executive Vice President, Commercial U.S.

Todd Simpson -- Chief Financial Officer

Roger Dansey -- Chief Medical Officer

Kennen MacKay -- RBC Capital Markets -- Analyst

Geoff Meacham -- Bank of America Merrill Lynch -- Analyst

Cory Kasimov -- J.P. Morgan -- Analyst

Salveen Richter -- Goldman Sachs -- Analyst

Matthew Harrison -- Morgan Stanley -- Analyst

Michael Schmidt -- Guggenheim Securities -- Analyst

Sheldon Chuan -- Barclays -- Analyst

Andy Hsieh -- William Blair -- Analyst

Andrew Berens -- SVB Leerink -- Analyst

Jay Olson -- Oppenheimer & Co. Inc. -- Analyst

More SGEN analysis

All earnings call transcripts

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$141.39 (2.12%) $2.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.